HLA-B*1502 haplotype screening prior to carbamazepine administration in individuals of south-east Asian ancestry nears cost-effectiveness in preventing severe cutaneous adverse drug reactions-Reference-Cited by-同舟云学术

HLA-B*1502 haplotype screening prior to carbamazepine administration in individuals of south-east Asian ancestry nears cost-effectiveness in preventing severe cutaneous adverse drug reactions

Published:2017-12-11 Issue:3 Volume:59 Page:245-246
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Australas J Dermatol

Author:

Kim Emma¹,McCrossin Ian²,Frew John W¹²³^ORCID

Affiliation:

1. University of New South Wales; Sydney New South Wales Australia

2. Department of Dermatology; Liverpool Hospital; Sydney New South Wales Australia

3. Ingham Institute of Applied Medical Research; Sydney New South Wales Australia

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajd.12754/fullpdf

Reference8 articles.

1. A marker for Stevens-Johnson syndrome;Chung;Nature,2004

2. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry;Diphoorn;Pharmacoepidemiol. Drug Saf.,2016

3. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK;Frey;J. Invest. Dermatol.,2017

4. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations;Ferrell;Pharmacogenomics,2008

5. European Medicines Agency 2012 PhVWP monthly report on safety concerns, guidelines and general matters: 2012; 1207 http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/07/WC500130391.pdf

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy;JAMA Dermatology;2024-06-01

2. Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at‐risk patients;Medical Journal of Australia;2023-08-06

3. Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings;Annual Review of Pharmacology and Toxicology;2021-01-06